Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, as well as in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274, a novel cardiac myosin inhibitor, which is in Phase I clinical trial for the potential treatment of hypertrophic cardiomyopathy; and AMG 594, a novel cardiac troponin activator that is in Phase I clinical trial. The company has strategic alliances with Amgen Inc. and Astellas Pharma Inc. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone650-624-3000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$31.50 million
Profitability
Miscellaneous
Employees130
Next Earnings Date4/25/2019 (Estimated)
OptionableOptionable
Cytokinetics (NASDAQ:CYTK) Frequently Asked Questions
What is Cytokinetics' stock symbol?
Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."
How were Cytokinetics' earnings last quarter?
Cytokinetics, Inc. (NASDAQ:CYTK) announced its earnings results on Thursday, February, 21st. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, topping analysts' consensus estimates of ($0.51) by $0.03. The biopharmaceutical company had revenue of $9.38 million for the quarter, compared to analyst estimates of $3.46 million. Cytokinetics had a negative return on equity of 168.21% and a negative net margin of 337.42%. View Cytokinetics' Earnings History.
When is Cytokinetics' next earnings date?
What guidance has Cytokinetics issued on next quarter's earnings?
Cytokinetics updated its FY 2019 earnings guidance on Thursday, February, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $28-32 million, compared to the consensus revenue estimate of $28.87 million.
What price target have analysts set for CYTK?
4 analysts have issued 12-month price targets for Cytokinetics' shares. Their predictions range from $10.00 to $21.00. On average, they expect Cytokinetics' stock price to reach $14.50 in the next year. This suggests a possible upside of 64.2% from the stock's current price. View Analyst Price Targets for Cytokinetics.
What is the consensus analysts' recommendation for Cytokinetics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cytokinetics.
What are Wall Street analysts saying about Cytokinetics stock?
Here are some recent quotes from research analysts about Cytokinetics stock:
- 1. HC Wainwright analysts commented, "Valuation and potential impediments to achieving it. We maintain our Buy rating and $21 price target. We highlight that omecamtiv, partnered globally with Amgen, drives the lion’s share of our current valuation (>80%). Reldesemtiv (CK-107) represents the remainder of the contribution to our valuation (15.1% for SMA and 3.5% for ALS) with no contribution from the pipeline. We highlight that our projections for reldesemtiv in ALS could be considered quite conservative (10% chance of success for late Phase 2 asset and $750 million peak sales) but takes into consideration the underlying perceived risk for ALS. Our price target is based on our clinical net present value (NPV) model." (3/19/2019)
- 2. According to Zacks Investment Research, "Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. " (2/26/2019)
- 3. Cantor Fitzgerald analysts commented, "We have an Overweight rating based on ome’ in chronic HF and relde’ in SMA & ALS. For ome’, GALACTIC-HF data are expected in 2021, with interim reads in ’19 (futility) and ’20 (efficacy) that may lead to milestone payments to CYTK. Recent relde’ P2 data in SMA showed clinical benefit in 6MWD & MEP which enhances PoS in Type III SMA in our view. With VITALITY-ALS lessons learned & SMA PoC in hand, we are cautiously optimistic on relde’ prospects and believe investors may be overlooking potential value creation within the next 12 months." (12/5/2018)
Has Cytokinetics been receiving favorable news coverage?
Press coverage about CYTK stock has trended somewhat negative on Tuesday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cytokinetics earned a daily sentiment score of -1.4 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near future.
Who are some of Cytokinetics' key competitors?
Some companies that are related to Cytokinetics include AnaptysBio (ANAB), Mallinckrodt (MNK), Endo International (ENDP), Enanta Pharmaceuticals (ENTA), Heron Therapeutics (HRTX), Supernus Pharmaceuticals (SUPN), Xencor (XNCR), Arrowhead Pharmaceuticals (ARWR), Myovant Sciences (MYOV), Zai Lab (ZLAB), Allakos (ALLK), Pacira Pharmaceuticals (PCRX), Opko Health (OPK), Puma Biotechnology (PBYI) and Prestige Consumer Healthcare (PBH).
What other stocks do shareholders of Cytokinetics own?
Who are Cytokinetics' key executives?
Cytokinetics' management team includes the folowing people:
- Mr. Robert I. Blum, CEO, Pres & Director (Age 55)
- Mr. Ching W. Jaw, Sr. VP & CFO (Age 56)
- Dr. Andrew A. Wolff, Sr. VP & Chief Medical Officer (Age 64)
- Dr. Fady Ibraham Malik, Exec. VP of R&D (Age 55)
- Dr. Bradley Paul Morgan, Sr. VP of Research & Non-Clinical Devel. (Age 59)
Who are Cytokinetics' major shareholders?
Cytokinetics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.95%), Great Point Partners LLC (5.80%), FMR LLC (3.39%), Pinnacle Associates Ltd. (1.08%), Bank of New York Mellon Corp (1.08%) and Geode Capital Management LLC (1.07%). Company insiders that own Cytokinetics stock include Bradley Paul Morgan, Caryn Gordon Mcdowell, Fady Ibraham Malik, Robert I Blum and Santo J Costa. View Institutional Ownership Trends for Cytokinetics.
Which major investors are selling Cytokinetics stock?
CYTK stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, FMR LLC, Pinnacle Associates Ltd., Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, Barclays PLC, Northern Trust Corp and Virtus ETF Advisers LLC. Company insiders that have sold Cytokinetics company stock in the last year include Fady Ibraham Malik and Robert I Blum. View Insider Buying and Selling for Cytokinetics.
Which major investors are buying Cytokinetics stock?
CYTK stock was bought by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Fosun International Ltd, Foresite Capital Management IV LLC, Citigroup Inc., ClariVest Asset Management LLC, Geode Capital Management LLC, Geode Capital Management LLC and D. E. Shaw & Co. Inc.. View Insider Buying and Selling for Cytokinetics.
How do I buy shares of Cytokinetics?
Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cytokinetics' stock price today?
One share of CYTK stock can currently be purchased for approximately $8.83.
How big of a company is Cytokinetics?
Cytokinetics has a market capitalization of $484.68 million and generates $31.50 million in revenue each year. The biopharmaceutical company earns $-106,290,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis. Cytokinetics employs 130 workers across the globe.
What is Cytokinetics' official website?
How can I contact Cytokinetics?
Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]
MarketBeat Community Rating for Cytokinetics (NASDAQ CYTK)
MarketBeat's community ratings are surveys of what our community members think about Cytokinetics and other stocks. Vote "Outperform" if you believe CYTK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYTK will underperform the S&P 500 over the long term. You may vote once every thirty days.
